Many people with ovarian cancer are offered genetic testing at diagnosis to see if their cancer is related to an inherited gene mutation (for example a change in the BRCA1 or BRCA2 gene.) Knowing if there are any inherited gene mutations can help doctors offer the best treatment plans, prevent other cancers developing and offer potential testing of…

The purpose of this trial is to find out how safe and effective it is to have either one or two immunotherapy drugs alongside the parp inhibitor Rucaparib. Researchers want to find out if using the different combination of drugs will prolong the time it takes for your cancer to come back compared with being treated with Rucaparib on its own. The…

Olaparib is a type of targeted treatment known as a PARP inhibitor. It blocks an enzyme called PARP, which helps damaged cancer cells to repair themselves. When PARP doesn't work the cancer cells won't be able to repair themselves and will die. Because of this, drugs such as olaparib are known to lengthen the amount of time between receiving chemot…

The FORECEE (4C) research project is a new major study investigating the risk of breast, ovarian, womb and cervical cancer. Hormones are known to drive the development of particular diseases in women. Cervical cells are sensitive to the body’s own hormone levels in ways that are similar to the breast and other reproductive organs. This means tha…

In this trial, the researchers are trying to find out whether it's safe and effective to use a PARP inhibitor rather than standard chemotherapy in women with a BRCA gene mutation who've had two previous chemotherapy treatments. The drugs involved in this trial: Rucaparib – a targeted treatment known as a PARP inhibitor Paclitaxel – a sta…